Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
From Horizon Therapeutics plc
Via Business Wire
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
From Horizon Therapeutics plc
Via Business Wire
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Conferences
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
From Horizon Therapeutics plc
Via Business Wire
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
From Horizon Therapeutics plc
Via Business Wire
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
From Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.